Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib, ABBV-105 and ABBV-599 in Moderate to Severe Active SLE
CTR20192719Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of upadacitinib, elsubrutinib, ABBV-599 in systemic lupus erythematosus (SLE), sponsored by AbbVie Inc.. Started Apr 2020; status: completed.
02
Drugs
upadacitinibelsubrutinibABBV-599
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20192719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192719.